Suchergebnisse - "Pinato, David J"

PubPharm (10)

1

Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer

enthalten in: BJU international | 2022

von Makrakis, D. | Talukder, R. | Diamantopoulos, L. | +44

2

Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy

enthalten in: Thoracic cancer | 2022

von Banna, G. | Tiseo, M. | Cortinovis, D. | +31

3

Immunotherapy in Hepatocellular Carcinoma

enthalten in: Current treatment options in oncology | 2021

von Fulgenzi, C. | Talbot, T. | Murray, S. | +4

4

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Cortellini, A. | Cannita, K. | Tiseo, M. | +49

CommentIn: Eur J Cancer. 2021 Sep;155:294-295. - PMID 34364743

5

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

enthalten in: Nature | 2021

von Pfister, D. | Núñez, N. | Pinyol, R. | +98

CommentIn: Nat Rev Cancer. 2021 Jun;21(6):341. - PMID 33864034

6

Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours

enthalten in: Neuroendocrinology | 2021

von Pinato, D. | Vallipuram, A. | Evans, J. | +9

7

Impact of performance status on treatment outcomes : A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors

enthalten in: Cancer | 2020

von Khaki, A. | Li, A. | Diamantopoulos, L. | +34

8

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma : the Blueprint-HCC study

enthalten in: British journal of cancer | 2019

von Pinato, D. | Mauri, F. | Spina, P. | +12

9

PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity

enthalten in: Immunotherapy | 2019

von Black, J. | Goldin, R. | Foxton, M. | +6

10

enthalten in: Journal of clinical pathology | 2018

von Kythreotou, A. | Siddique, A. | Mauri, F. | +2

1
[1]